These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21129604)

  • 1. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.
    De Vita F; Giuliani F; Silvestris N; Catalano G; Ciardiello F; Orditura M
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S11-5. PubMed ID: 21129604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
    Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
    Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted HER2 treatment in advanced gastric cancer.
    Jørgensen JT
    Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases.
    Al-Batran SE; Hozaeel W; Jäger E
    Onkologie; 2012; 35(9):505-8. PubMed ID: 23007148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab in gastric cancer.
    Okines AF; Cunningham D
    Eur J Cancer; 2010 Jul; 46(11):1949-59. PubMed ID: 20542421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
    Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy for gastric cancer--current status.
    Kulig J; Kołodziejczyk P; Kulig P; Legutko J
    J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
    Lorenzen S; Lordick F
    Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
    Bouché O; Penault-Llorca F
    Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab for gastric cancer.
    Meza-Junco J; Au HJ; Sawyer MB
    Expert Opin Biol Ther; 2009 Dec; 9(12):1543-51. PubMed ID: 19916733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
    Bang YJ
    J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.
    Satoh T; Omuro Y; Sasaki Y; Hamamoto Y; Boku N; Tamura T; Ohtsu A
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):949-55. PubMed ID: 22116464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
    Lordick F
    Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy].
    Nishi T; Hamamoto Y; Uemoto J; Onodera K; Warita E; Yamanaka Y
    Gan To Kagaku Ryoho; 2012 Dec; 39(13):2553-5. PubMed ID: 23235178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab plus chemotherapy in gastric cancer overexpressing HER-2 and EGFR: a case report.
    Al-Batran SE; Ruppert M; Jäger E
    Onkologie; 2011; 34(1-2):42-5. PubMed ID: 21346384
    [No Abstract]   [Full Text] [Related]  

  • 18. Lapatinib in breast cancer: clinical experiences and future perspectives.
    Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab for gastric cancer treatment.
    Fujita T
    Lancet; 2010 Nov; 376(9754):1735; author reply 1735-6. PubMed ID: 21093641
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.